First National Advisers’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.83M Buy
23,174
+2,351
+11% +$506K 0.82% 24
2026
Q1
$4.53M Sell
20,823
-2,952
-12% -$655K 0.66% 29
2025
Q4
$5.43M Buy
23,775
+229
+1% +$52.2K 0.75% 26
2025
Q3
$5.45M Buy
23,546
+1,133
+5% +$231K 0.74% 27
2025
Q2
$4.16M Buy
22,413
+21,388
+2,087% +$3.97M 0.61% 42
2025
Q1
$215K Buy
+1,025
New +$199K 0.03% 210
2024
Q2
Sell
-1,611
Closed -$293K 209
2024
Q1
$293K Buy
+1,611
New +$278K 0.07% 180
2022
Q4
Sell
-600
Closed -$81K 109
2022
Q3
$81K Buy
+600
New +$86.1K 0.12% 125

Other funds holding ABBV

First National Advisers's ABBV Position: Q2 2026 in Review

First National Advisers increased its AbbVie (ABBV) stake by 11% in Q2 2026, buying an estimated $506K and bringing the position to 23,174 shares worth $5.83M. The position accounts for 0.82% of the portfolio, ranked #24.

First National Advisers first reported a position in ABBV in Q3 2022 and has held it in 8 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • First National Advisers held 23,174 shares of AbbVie worth $5.83M as of Q2 2026.
  • First National Advisers bought 2,351 AbbVie shares in Q2 2026, an estimated $506K.
  • AbbVie made up 0.82% of First National Advisers's portfolio in Q2 2026, its #24 holding.
  • First National Advisers first reported a position in AbbVie in Q3 2022 and has held it in 8 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on First National Advisers's 13F filing for Q2 2026, filed 21 Jul 2026.